Search results for "Estrogen"

showing 10 items of 530 documents

Aging Negatively Affects Estrogens-Mediated Effects on Nitric Oxide Bioavailability by Shifting ERα/ERβ Balance in Female Mice

2011

AIMS: Aging is among the major causes for the lack of cardiovascular protection by estrogen (E2) during postmenopause. Our study aims to determine the mechanisms whereby aging changes E2 effects on nitric oxide (NO) production in a mouse model of accelerated senescence (SAM). METHODS AND RESULTS: Although we found no differences on NO production in females SAM prone (SAMP, aged) compared to SAM resistant (SAMR, young), by either DAF-2 fluorescence or plasmatic nitrite/nitrate (NO2/NO3), in both cases, E2 treatment increased NO production in SAMR but had no effect in SAMP. Those results are in agreement with changes of eNOS protein and gene expression. E2 up-regulated eNOS expression in SAMR…

AgingAnatomy and Physiologylcsh:MedicineEstrogen receptorFluorescent Antibody TechniqueCardiovascularCardiovascular SystemBiochemistrychemistry.chemical_compoundMiceEndocrinologyEnosMolecular Cell BiologyMembrane Receptor Signalinglcsh:ScienceReceptorMultidisciplinarybiologySuperoxideNeurochemistryHormone Receptor SignalingReceptors EstrogenDNA methylationCirculatory PhysiologyMedicineFemaleNeurochemicalsResearch ArticleSignal TransductionSenescencemedicine.medical_specialtymedicine.drug_classBlotting WesternEndocrine SystemNitric OxideReal-Time Polymerase Chain ReactionCardiovascular PharmacologyNitric oxideInternal medicinemedicineCardiovascular Diseases in WomenAnimalsBiologyEndocrine Physiologylcsh:RNADPH OxidasesEstrogensDNA Methylationbiology.organism_classificationHormonesEndocrinologychemistryEstrogenWomen's Healthlcsh:QNeurosciencePLoS ONE
researchProduct

Power training and postmenopausal hormone therapy affect transcriptional control of specific co-regulated gene clusters in skeletal muscle

2010

At the moment, there is no clear molecular explanation for the steeper decline in muscle performance after menopause or the mechanisms of counteractive treatments. The goal of this genome-wide study was to identify the genes and gene clusters through which power training (PT) comprising jumping activities or estrogen containing hormone replacement therapy (HRT) may affect skeletal muscle properties after menopause. We used musculus vastus lateralis samples from early stage postmenopausal (50–57 years old) women participating in a yearlong randomized double-blind placebo-controlled trial with PT and HRT interventions. Using microarray platform with over 24,000 probes, we identified 665 diffe…

AgingCandidate geneTranscription GeneticvaihdevuodetmenopaussiBioinformaticsEstrogen deprivation0302 clinical medicineGene expressionestrogenTranscriptional regulation0303 health sciencesEstrogen Replacement TherapyGeneral MedicineMiddle AgedestrogeeniPostmenopausemedicine.anatomical_structureFemalevoimaharjoitteluMenopausemedicine.symptomTranscriptome-wide studymedicine.medical_specialtyPlyometric trainingmedicine.drug_classBiologyArticletranskriptomin laajuuinen tutkimus03 medical and health sciencesplyometrinen harjoitteluInternal medicinemedicineHumansSkeletal muscle characteristicsKEGGMuscle SkeletalExerciseGene030304 developmental biologyhormonikorvaushoitoSkeletal muscleMuscle weaknessdeprivaatioPower trainingAgeingEndocrinologyluurankolihaksetHormone replacement therapyEstrogenGeriatrics and Gerontology030217 neurology & neurosurgeryAGE
researchProduct

Regulatory mechanisms of estrogen on vascular ageing

2019

Women can be considered hemodynamically younger than men of the same age, based on epidemiological studies establishing that the incidence of vascular diseases in women is relatively lower compared to that in aged-matched men. However, after menopause, these numbers increase to values that are close to those found in men. Vascular ageing is associated with structural and functional changes of the vascular wall, including endothelial dysfunction, arterial stiffening, and remodelling, as well as impaired angiogenesis, which become major risk factors in the development of cardiovascular disease.

AgingEndotheliumArticle Subjectbusiness.industrymedicine.drug_classlcsh:CytologyEstrogensCell BiologyGeneral MedicineBioinformaticsBiochemistryVascular ageingmedicine.anatomical_structureText miningEditorialEstrogenMedicineHumansFisiologia humanaFemaleEndothelium Vascularlcsh:QH573-671businessSistema cardiovascular
researchProduct

Lifelong soya consumption in males does not increase lifespan but increases health span under a metabolic stress such as type 2 diabetes mellitus.

2021

Soya consumption can decrease oxidative stress in animal models. Moreover, phytoestrogens such as genistein, present in soya, can mimic some of the beneficial effects of estrogens and are devoid of significant side effects, such as cancer. In this study, we have performed a controlled lifelong study with male OF1 mice that consumed either a soya-free diet or a soya-rich diet. We show that, although we found an increase in the expression and activity of antioxidant enzymes in soya-consuming mice, it did not increase lifespan. We reasoned that the soya diet could not increase lifespan in a very healthy population, but perhaps it could extend health span in stressed animals such as type 2 diab…

Agingmedicine.medical_specialtyAntioxidantGoto Kakizaki ratsmedia_common.quotation_subjectmedicine.medical_treatmentLongevityGenisteinPhytoestrogensDiseasemedicine.disease_causeAntioxidants03 medical and health scienceschemistry.chemical_compoundfluids and secretions0302 clinical medicineStress PhysiologicalInternal medicineMedicineAnimals030304 developmental biologymedia_common2. Zero hunger0303 health sciencesbusiness.industryLongevityfood and beveragesType 2 Diabetes MellitusIsoflavonesAnimal FeedIsoflavones3. Good healthRatsOxidative StressEndocrinologychemistryDiabetes Mellitus Type 2Soya030220 oncology & carcinogenesisAntioxidant enzymesPhytoestrogensSoybeansbusinessOxidative stressDevelopmental BiologyMechanisms of ageing and development
researchProduct

Muscular transcriptome in postmenopausal women with or without hormone replacement.

2007

The loss of muscle mass and strength with aging is well characterized, but our knowledge of the molecular mechanisms underlying the development of sarcopenia remains incomplete. Although menopause is often accompanied with first signs of age-associated changes in muscle structure and function, the effects of hormone replacement therapy (HRT) or menopause-related decline in estrogen production in the muscles of postmenopausal women is not well understood. Furthermore the knowledge of the global transcriptional changes that take place in skeletal muscle in relation to estrogen status has thus far been completely lacking. We used a randomized double-blinded study design together with an explor…

Agingmedicine.medical_specialtyvaihdevuodetmedicine.drug_classmenopaussiBiologysarcopeniaTranscriptomeInternal medicinemedicineHumanssarkopeniaRNA Messengermuscular transcriptomeMuscle SkeletalOligonucleotide Array Sequence AnalysishormonikorvaushoitolihastranskriptomiRegulation of gene expressionPostmenopausal womenGene Expression ProfilingEstrogen Replacement TherapySkeletal muscleMiddle Agedmedicine.diseaseMenopauseGene expression profilingPostmenopausehormone replacement therapyEndocrinologymedicine.anatomical_structureGene Expression RegulationReceptors EstrogenEstrogenSarcopeniaFemalesense organsGeriatrics and GerontologyRejuvenation research
researchProduct

Intramuscular sex steroid hormones are associated with skeletal muscle strength and power in women with different hormonal status

2015

International audience; Estrogen (E2)-responsive peripheral tissues, such as skeletal muscle, may suffer from hormone deficiency after menopause potentially contributing to the aging of muscle. However, recently E2 was shown to be synthesized by muscle and its systemic and intramuscular hormone levels are unequal. The objective of the study was to examine the association between intramuscular steroid hormones and muscle characteristics in premenopausal women (n = 8) and in postmenopausal monozygotic twin sister pairs (n = 16 co-twins from eight pairs) discordant for the use of E2-based hormone replacement. Isometric skeletal muscle strength was assessed by measuring knee extension strength.…

Agingsteroidogenesismuscle steroidsMonozygotic twinIsometric exercise0302 clinical medicineMyocyteGonadal Steroid HormonesTestosteronemuscle performance0303 health sciences[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyEstrogen Replacement TherapyAge FactorsMENta3141Middle AgedPostmenopauseESTROGENmedicine.anatomical_structureDISCORDANTFemaleintracrine organAdultEXPRESSIONmedicine.medical_specialtymedicine.drug_classeducationDehydroepiandrosteroneEXERCISEBiologyMETABOLISMta3111MECHANISMS03 medical and health sciencesREPLACEMENT THERAPYSex FactorsInternal medicinemedicineHumansMuscle Skeletal030304 developmental biologyInfant NewbornSkeletal muscleOriginal ArticlesCell BiologyMONOZYGOTIC TWIN PAIRSCross-Sectional StudiesEndocrinologyPremenopauseEstrogenCase-Control Studies3121 General medicine internal medicine and other clinical medicinelocal hormone synthesis3111 Biomedicine030217 neurology & neurosurgery[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyHormone
researchProduct

Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist…

2005

Background This descriptive study evaluates the impact on endometrial development of standard and high doses of a GnRH antagonist in stimulated cycles compared with GnRH agonist and natural cycles. Methods Thirty-one oocyte donors were treated with a combination of rFSH and 0.25 mg/day ganirelix (standard dose), 2 mg/day ganirelix (high dose) or 0.6 mg/day buserelin (long protocol). Vaginal progesterone (200 mg/day) was administered in the luteal phase. Endometrial biopsies were performed 2 and 7 days after HCG administration. Additional biopsies were carried out in a subset of 12 subjects, 2 and 7 days following the LH peak of their previous natural cycle. Biopsies were evaluated histologi…

AgonistAdultendocrine systemmedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classmedicine.medical_treatmentFertilization in VitroLuteal phaseBiologyLuteal PhaseEndometriumBuserelinChorionic GonadotropinGonadotropin-releasing hormone antagonistGonadotropin-Releasing HormoneEndometriumOvulation InductionInternal medicinemedicineHumansUltrasonicsGanirelixOligonucleotide Array Sequence Analysismedicine.diagnostic_testOocyte DonationRehabilitationObstetrics and GynecologyBuserelinmedicine.anatomical_structureEndocrinologyReproductive MedicineGene Expression RegulationReceptors EstrogenMicroscopy Electron ScanningOocytesRNAOvulation inductionFemaleFollicle Stimulating HormoneReceptors Progesteronehormones hormone substitutes and hormone antagonistsmedicine.drugEndometrial biopsyHuman reproduction (Oxford, England)
researchProduct

Progesterone increases basal 3',5'-cyclic adenosine monophosphate formation and down-regulates the agonist-induced inositol phosphates generation in …

1992

Whether the placenta is a target tissue for estrogens and progesterone, and their putative mechanism of action, is still a controversial question in the literature. The effect of progesterone and estradiol on 3′,5′-cyclic adenosine monophosphate (cAMP) and inositol phosphates generation in human term placenta was investigated. Placental explants were incubated in vitro for up to 48 h in the absence and in the presence of estradiol, progesterone or both steroids (0.1 μmol/l final concentration in all cases), and were stimulated with terbutaline, a β-adrenergic agonist, (0.1 mmol/l) or angiotensin II(1 μmol/l), The cAMP content was measured by a competitive protein binding assay, and the gene…

Agonistmedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismInositol PhosphatesPlacentaDown-RegulationBiologychemistry.chemical_compoundEndocrinologyPregnancyInternal medicinePlacentamedicineCyclic AMPTerbutalineHumansCyclic adenosine monophosphateInositolInositol phosphateProgesteronechemistry.chemical_classificationLabor ObstetricEstradiolAngiotensin IIGeneral MedicineTrypan BlueChromatography Ion ExchangeAngiotensin IIEndocrinologymedicine.anatomical_structurechemistryEstrogenSecond messenger systemLactatesFemaleActa endocrinologica
researchProduct

Influence of hormonal treatment on the response of the rat isolated uterus to histamine and histamine receptor agonists.

1992

The response of the isolated uterus to histamine and histamine agonists was investigated in progesterone- and oestrogen-treated rats. The uterine inhibitory responses to histamine and 4-methylhistamine (a histamine H2 receptor agonist) were similar in KCl-contracted uteri from progesterone- and oestrogen-treated rats. The histamine H1 receptor agonist, 2-pyridyl-ethylamine, produced a relaxant response only in progesterone dominant uterus. This was inhibited by the histamine H1 receptor antagonist. In the rat isolated uterus which was not preconstricted by KCl, neither histamine, 4-methylhistamine, nor 2-pyridyl-ethylamine produced any effect in the presence or absence of ranitidine. Raniti…

Agonistmedicine.medical_specialtymedicine.drug_classPyridinesHistamine H1 receptorBiologyRanitidineHistamine agonistPotassium ChlorideRanitidinechemistry.chemical_compoundHistamine receptorUterine ContractionHistamine H2 receptorInternal medicinemedicineAnimalsDrug InteractionsHistamine H4 receptorProgesteronePharmacologyMethylhistaminesUterusEstrogensRats Inbred StrainsRatsEndocrinologychemistryReceptors HistamineFemaleHistaminemedicine.drugHistamineEuropean journal of pharmacology
researchProduct

Genistein effect on cognition in prodromal Alzheimer's disease patients : the GENIAL clinical trial

2022

Background: Delaying the transition from minimal cognitive impairment to Alzheimer’s dementia is a major concern in Alzheimer’s disease (AD) therapeutics. Pathological signs of AD occur years before the onset of clinical dementia. Thus, long-term therapeutic approaches, with safe, minimally invasive, and yet efective substances are recommended. There is a need to develop new drugs to delay Alzheimer’s dementia. We have taken a nutritional supplement approach with genistein, a chemically defned polyphenol that acts by multimodal specifc mechanisms. Our group previously showed that genistein supplementation is efective to treat the double transgenic (APP/PS1) AD animal model. Methods: In this…

Amyloid beta-PeptidesSoy isofavonesCognitive NeurosciencePhytoestrogensNeuronesGenisteinCognitive impairmentAmyloid-beta cingulate gyrusCognitionNeurologyAlzheimer DiseaseMalaltiesHumansCognitive DysfunctionNeurology (clinical)
researchProduct